Connect with us

Impact Investing

The Dow Jones Sustainability Index Shows Pharma Sector Is Less Green

The pharma sector faces a setback in sustainability, as AstraZeneca, Novartis, and Amgen, previously included in the Dow Jones Sustainability Index, are omitted in the latest edition. Despite AstraZeneca and Novartis making it to the European classification, the three companies were excluded globally. The DJSI comprises the top 10% of the 2,500 largest global corporations in the S&P Global Broad Market Index.



Dow Jones Sustainability Index

The  pharma  sector loses points in sustainability. The new edition of the  Dow Jones Sustainability Index  (Djsi) has left out three companies that were in the ranking a year ago, and all three are from the pharmaceutical sector: AstraZeneca, Novartis and Amgen.

The index, which highlights companies’ commitment to environmental, social and governance (ESG), included the three companies last year, but all three have now been left out of the global ranking, despite the fact that AstraZeneca and Novartis have entered in the European classification.

“In 2023 there has been another strong response from companies, which see the value of revealing their sustainability results to the capital markets,” the company noted. By market capitalization, the company has eliminated the three pharmaceutical companies from the global ranking, while it has added Tencent Holdings, Philip Morris International and ServiceNow.

The Dow Jones Sustainability Index is made up of those selected by S&P based on the Global Corporate Sustainability Assessment, through questionnaires designed to evaluate sustainability criteria that are financially relevant in economic, environmental and social dimensions. This time the index includes the top 10% of the 2,500 largest global corporations in the S&P Global Broad Market Index. 

Read more about the Dow Jones Sustainability Index and find the latest economic news of the day with the Born2Invest mobile app.

The Dow Jones Sustainability Index: Abbvie is recognized for criteria such as the environmental dimension

In the pharmaceutical area Abbvie is in the lead. The  American biopharma  is specialized in therapeutic areas such as immunology, oncology, neuroscience, eye care, virology and gastroenterology .

In the case of Abbvie, criteria are recognized such as the environmental dimension, contribution to health results, good corporate governance and economic dimension, as well as risk and crisis management, among other aspects.

Among the companies in the pharma sector, Grifols, a Spanish company specialized in the production of medicines derived from plasma, has been crowned as the Spanish and European biopharmaceutical company with the highest result in the index.

Grifols has been included in the Dow Jones Sustainability Index for the fourth consecutive year , distinguishing itself as a leader in the biotechnology sector which, this year (until November 24, 2023), includes 372 companies according to the Global Corporate Sustainability Assessment (CSA). 

Another of the companies in the sector in the noble part of the ranking is Biogen. The American neuroscience company discovers, develops and supplies innovative therapies for people living with serious neurological and neurodegenerative diseases, as well as related adjacent therapies. Biogen, one of the world’s first biotechnology companies, was founded in 1978  by Charles Weissmann, Heinz Schaller, Kenneth Murray, and Nobel Prize winners Walter Gilbert and Phillip Sharp.

At the moment, Biogen has a leading portfolio of medicines to treat multiple sclerosis, has introduced the first approved treatment for spinal muscular atrophy, and has developed  the first and only approved treatment that addresses a defining pathology of Alzheimer’s Disease.


(Featured image by Markus Spiske via Pexels)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.

Jeremy Whannell loves writing about the great outdoors, business ventures and tech giants, cryptocurrencies, marijuana stocks, and other investment topics. His proficiency in internet culture rivals his obsession with artificial intelligence and gaming developments. A biker and nature enthusiast, he prefers working and writing out in the wild over an afternoon in a coffee shop.